Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Tufts model estimates 82x ROI and up to $21 million in value from Medable AI agent

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at drugdiscoverytrends.com →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

Tufts Center for the Study of Drug Development and Medable estimate Medable's Clinical Monitoring Agent delivers an 82x ROI for phase 3 oncology trials and a $21 million financial value increase, highlighting significant efficiency gains and value creation in clinical trial monitoring.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

You now have a clear financial case for integrating AI agents in oncology trials to cut costs and speed up monitoring. Deploying Medable’s solution can unlock millions in saved time and capital, reshaping clinical trial operations.

◆ Coverage

1 source · 26 Aug 2026

◆ Related on Wire

◆ Topics

Drug Discoveryclinical-trialsai-agentsroi-estimateoncologymedtech